% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Primac:304482,
      author       = {I. Primac and K. Tabury and A. Tasdogan$^*$ and S. Baatout
                      and K. Herrmann$^*$},
      title        = {{T}he molecular blueprint of targeted radionuclide
                      therapy.},
      journal      = {Nature reviews / Clinical oncology},
      volume       = {nn},
      issn         = {1759-4774},
      address      = {New York, NY},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2025-01874},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {Targeted radionuclide therapy (TRT) is a cutting-edge
                      treatment approach in oncology that combines the molecular
                      precision of targeted agents with the effect of radiotherapy
                      to selectively deliver cytotoxic radiation to cancer cells.
                      Research efforts from the past few decades have led to a
                      diverse molecular landscape of TRT and have provided lessons
                      for further rational development of targeted
                      radiopharmaceuticals and expansion of the clinical
                      applications of this treatment modality. In this Review, we
                      discuss TRT in the context of therapeutic approaches
                      currently available in oncology, describe the broad range of
                      established and emerging targets for TRT including
                      innovative approaches to exploit vulnerabilities presented
                      by the tumour microenvironment, and address the challenges
                      for clinical translation and molecular optimization. By
                      bridging technological innovation and preclinical
                      discoveries with real-world clinical implementation, ongoing
                      research on TRT is seeking to provide effective and safe
                      treatment options for patients across a variety of cancer
                      types and treatment settings. Overall, we emphasize the
                      transformative potential of TRT and highlight how a
                      comprehensive understanding of what constitutes an optimal
                      target can redefine clinical practice, fostering the
                      evolution of TRT as a highly individualized and adaptable
                      therapeutic option that improves outcomes across a broad
                      range of cancer types.},
      subtyp        = {Review Article},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40926013},
      doi          = {10.1038/s41571-025-01069-z},
      url          = {https://inrepo02.dkfz.de/record/304482},
}